BI to foil physician penny pinching with Pradaxa UK price cut
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim will be cutting the UK list price for its warfarin replacement Pradaxa (dabigatran etexilate) by 13%, says the firm, just weeks after it won NICE recommendations for stroke prevention. The company hopes the move will stop doctors from declining to prescribe the drug because of "short term costing issues".